Diabetes and infection: review of the epidemiology, mechanisms and principles of treatment
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
An association between diabetes and infection has been recognised for many years, with infection being an important cause of death and morbidity in people with diabetes. The COVID-19 pandemic has re-kindled an interest in the complex relationship between diabetes and infection. Some infections occur almost exclusively in people with diabetes, often with high mortality rates without early diagnosis and treatment. However, more commonly, diabetes is a complicating factor in many infections. A reciprocal relationship occurs whereby certain infections and their treatments may also increase the risk of diabetes. People with diabetes have a 1.5- to 4-fold increased risk of infection. The risks are the most pronounced for kidney infection, osteomyelitis and foot infection, but are also increased for pneumonia, influenza, tuberculosis, skin infection and general sepsis. Outcomes from infection are worse in people with diabetes, with the most notable example being a twofold higher rate of death from COVID-19. Hyperglycaemia has deleterious effects on the immune response. Vascular insufficiency and neuropathy, together with altered skin, mucosal and gut microbial colonisation, contribute to the increased risk of infection. Vaccination is important in people with diabetes although the efficacy of certain immunisations may be compromised, particularly in the presence of hyperglycaemia. The principles of treatment largely follow those of the general population with certain notable exceptions. Graphical Abstract
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive versus Conventional Glucose Control in Critically Ill Patients
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810625 · Cited by 5,119 · cited 1×
“In a landmark study examining the effects of glycaemic management in people admitted to the ICU, among whom one-fifth had sepsis, lowering of blood glucose to 4.5–6.0 mmol/l did not lead to improved outcomes compared with moderate blood glucose targets of ≤10 mmol/l [105].”
BackgroundInfluentialAssiri, A., Al-Tawfiq, J. A., Al-Rabeeah, A. A., Al-Rabiah, F. A., Al-Hajjar, S., Al-Barrak, A., Flemban, H., Al-Nassir, W. N., Balkhy, H. H., Al-Hakeem, R. F., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70204-4 · Cited by 1,435
Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection
Thaiss, C. A., Levy, M., Grosheva, I., Zheng, D., Soffer, E., Blacher, E., Braverman, S., Tengeler, A. C., Barak, O., Elazar, M., et al. (2018) · Science · doi:10.1126/science.aar3318 · Cited by 942 · cited 2×
“In addition to this being considered an important contributor to the metabolic dysfunction and insulin resistance [56], the microbiome contributes to the increased risk of enteric and other systemic infections in diabetes [49, 57].”
BackgroundPalmer, S. C., Tendal, B., Mustafa, R. A., Vandvik, P. O., Li, S., Hao, Q., Tunnicliffe, D., Ruospo, M., Natale, P., Saglimbene, V., et al. (2021) · BMJ · doi:10.1136/bmj.m4573 · Cited by 679 · cited 1×
“The use of sodium–glucose cotransporter 2 (SGLT-2) inhibitors is associated with increased risk of genital tract infections but not urinary tract infections [84].”
BackgroundRisks and burdens of incident diabetes in long COVID: a cohort study
Xie, Y., & Al-Aly, Z. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00044-4 · Cited by 564
Physical interventions to interrupt or reduce the spread of respiratory viruses
Jefferson, T., Dooley, L., Ferroni, E., Al-Ansary, L. A., van Driel, M. L., Bawazeer, G. A., Jones, M. A., Hoffmann, T. C., Clark, J., Beller, E. M., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006207.pub6 · Cited by 291
Viral infections in type 1 diabetes mellitus — why the β cells?
Op de Beeck, A., & Eizirik, D. L. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.30 · Cited by 291
Lustig, Y., Sapir, E., Regev-Yochay, G., Cohen, C., Fluss, R., Olmer, L., Indenbaum, V., Mandelboim, M., Doolman, R., Amit, S., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3790408 · Cited by 4
Cited by
Retatrutide—A Game Changer in Obesity Pharmacotherapy
Katsi, V., Koutsopoulos, G., Fragoulis, C., Dimitriadis, K., & Tsioufis, K. (2025) · Biomolecules · doi:10.3390/biom15060796 · Cited by 29
“The presence of T2DM also increases susceptibility to a variety of cancers (such as liver, biliary tract, pancreas, stomach, colorectal, kidney, bladder, breast, and endometrial) and infections (like respiratory, urinary tract, and skin and soft tissue infections) [6].”
Risk of infection in older adults with type 2 diabetes with relaxed glycemic control
Lipska, K. J., Gilliam, L. K., Lee, C., Liu, J. Y., Liu, V. X., Moffet, H. H., Parker, M. M., Zapata, H., & Karter, A. J. (2024) · Diabetes Care · doi:10.2337/dc24-1612 · Cited by 7
Metadata
- Authors
- Holt, R. I. G., Cockram, C. S., Ma, R. C. W., & Luk, A. O. Y.
- Venue
- Diabetologia
- Published
- 2024-02-20
- Volume
- 67
- Issue
- 7
- Pages
- 1168-1180
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W4391980988
- Cited by
- 250
- References
- 8
- FWCI
- 67.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diabetes and infection: review of the epidemiology, mechanisms and principles of treatment. https://app.cochat.ai/papers/10.1007/s00125-024-06102-x
- The paper
- Holt, R. I. G., Cockram, C. S., Ma, R. C. W., & Luk, A. O. Y. (2024). Diabetes and infection: review of the epidemiology, mechanisms and principles of treatment. Diabetologia. https://doi.org/10.1007/s00125-024-06102-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.